SUPERNUS PHARMACEUTICALS, INC. Current Liabilities
SUPERNUS PHARMACEUTICALS, INC. (SUPN) had Current Liabilities of $347.38 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-03
- 2026-06-30: Liabilities, Current $347.38M.
- 2026-03-31: Liabilities, Current $373.93M.
- 2025-12-31: Liabilities, Current $338.17M.
- 2025-09-30: Liabilities, Current $330.63M.
| Period end | Liabilities, Current | Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $347.38M 10-Q · filed 2026-08-03 | |
| 2026-03-31 | $373.93M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $338.17M 10-Q · filed 2026-08-03 | |
| 2025-09-30 | $330.63M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $286.36M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $281.77M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $292.40M 10-K · filed 2026-03-02 | |
| 2024-09-30 | $291.51M 10-Q · filed 2024-11-04 | |
| 2024-06-30 | $308.66M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $314.55M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $290.20M 10-K · filed 2025-02-25 | |
| 2023-09-30 | $287.53M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $252.59M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $731.54M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $687.96M 10-Q · filed 2023-11-08 | |
| 2022-09-30 | $725.99M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $735.54M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $284.56M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $315.38M 10-K · filed 2023-03-09 | |
| 2021-09-30 | $234.71M 10-Q · filed 2021-11-05 | |
| 2021-06-30 | $283.45M 10-Q · filed 2021-08-06 | |
| 2021-03-31 | $240.81M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $245.11M 10-K · filed 2022-04-13 | |
| 2020-09-30 | $299.61M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $269.28M 10-Q · filed 2020-08-17 | |
| 2020-03-31 | $168.34M 10-Q · filed 2020-05-15 | |
| 2019-12-31 | $160.59M 10-K · filed 2021-03-08 | |
| 2019-09-30 | $149.72M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $143.97M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $151.71M 10-Q · filed 2019-05-10 | |
| 2018-12-31 | $161.35M 10-K · filed 2020-02-28 | |
| 2018-09-30 | $138.35M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $103.93M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $119.09M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $123.00M 10-K · filed 2019-03-01 | |
| 2017-09-30 | $104.96M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $85.52M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $82.00M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $80.74M 10-K · filed 2018-03-01 | |
| 2016-09-30 | $71.65M 10-Q · filed 2017-01-20 | |
| 2016-06-30 | $67.51M 10-Q/A · filed 2017-01-23 | $65.57M 10-Q · filed 2016-08-05 |
| 2016-03-31 | $55.53M 10-Q/A · filed 2017-01-20 | $54.12M 10-Q · filed 2016-05-10 |
| 2015-12-31 | $56.93M 10-K · filed 2017-03-16 | $56.10M 10-K · filed 2016-03-09 |
| 2015-09-30 | $43.69M 10-Q/A · filed 2017-01-20 | $43.13M 10-Q · filed 2015-11-09 |
| 2015-06-30 | $36.63M 10-Q/A · filed 2017-01-23 | $36.41M 10-Q · filed 2015-08-07 |
| 2015-03-31 | $27.51M 10-Q/A · filed 2017-01-20 | $26.86M 10-Q · filed 2015-05-06 |
| 2014-12-31 | $28.12M 10-Q/A · filed 2017-01-20 | $27.49M 10-K · filed 2015-03-12 |
| 2014-09-30 | $22.13M 10-Q/A · filed 2017-01-20 | |
| 2014-06-30 | $19.19M 10-Q · filed 2014-08-12 | |
| 2014-03-31 | $27.10M 10-Q · filed 2014-05-13 | |
| 2013-12-31 | $26.40M 10-K · filed 2015-03-12 | |
| 2013-09-30 | $25.07M 10-Q · filed 2013-11-13 | |
| 2013-06-30 | $16.02M 10-Q · filed 2013-08-14 | |
| 2013-03-31 | $27.01M 10-Q · filed 2013-05-15 | |
| 2012-12-31 | $22.98M 10-K · filed 2014-03-21 | |
| 2012-09-30 | $24.59M 10-Q · filed 2012-11-02 | |
| 2012-06-30 | $21.88M 10-Q · filed 2012-08-13 | |
| 2012-03-31 | $19.91M 10-Q · filed 2012-06-08 | |
| 2011-12-31 | $18.77M 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |